These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34560013)
41. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411 [TBL] [Abstract][Full Text] [Related]
42. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992 [TBL] [Abstract][Full Text] [Related]
43. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381 [TBL] [Abstract][Full Text] [Related]
44. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029 [TBL] [Abstract][Full Text] [Related]
45. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931 [TBL] [Abstract][Full Text] [Related]
46. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142 [TBL] [Abstract][Full Text] [Related]
47. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. Patrick K; Wade R; Goulden N; Rowntree C; Hough R; Moorman AV; Mitchell CD; Vora A Br J Haematol; 2014 May; 165(4):552-5. PubMed ID: 24428704 [TBL] [Abstract][Full Text] [Related]
48. Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria. Ronceray L; Dworzak M; Dieckmann K; Ebetsberger-Dachs G; Glogova E; Haas OA; Jones N; Nebral K; Moser R; Lion T; Meister B; Panzer-Grümayer R; Strehl S; Peters C; Pötschger U; Urban C; Mann G; Attarbaschi A; Wien Klin Wochenschr; 2024 Jul; 136(13-14):405-418. PubMed ID: 37535134 [TBL] [Abstract][Full Text] [Related]
49. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia. Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698 [TBL] [Abstract][Full Text] [Related]
50. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563 [TBL] [Abstract][Full Text] [Related]
52. Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study. Lin S; Liao N; Li X; Yang L; He YY; Tang YL; Wan WQ; Jia W; Zhang YJ; Kong Q; Long X; Lan X; Ling YY; Lin D; Zhang XL; Wen C; Li CK; Xu HG Eur J Haematol; 2024 Sep; 113(3):357-370. PubMed ID: 38847134 [TBL] [Abstract][Full Text] [Related]
53. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428 [TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989 [TBL] [Abstract][Full Text] [Related]
55. [Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion]. Zheng YZ; Li J; LE SH; Zheng H; Hua XL; Chen ZS; Hu JD Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):690-695. PubMed ID: 31315770 [TBL] [Abstract][Full Text] [Related]
56. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790 [TBL] [Abstract][Full Text] [Related]